Darolutamide for Non-Metastatic Castration-Resistant Prostate Cancer
May 11th 2020In July 2019, the FDA approved darolutamide (Nubeqa, Bayer) for men with prostate cancer that has not spread (ie, nonmetastatic) and no longer responds to medical or surgical treatment that lowers testosterone (ie androgen deprivation therapy).
FDA Issues Emergency Use Authorization for Remdesivir in COVID-19
May 1st 2020Officials with the FDA have issued an emergency use authorization for remdesivir (Gilead Sciences) for the treatment of suspected or laboratory-confirmed coronavirus disease 2019 (COVID-19) in hospitalized adults and children.